Capecitin Tablet 500 mg is an oral chemotherapy medication used in the treatment of various cancers, including breast cancer, colorectal cancer, and gastric cancer. It is a prodrug that is converted into the active drug 5-fluorouracil (5-FU) in the body, which inhibits cancer cell growth and proliferation.
Capecitin Tablet 500 mg is primarily used for:
| Brand Name | Capecitin |
|---|---|
| Type | Tablet |
| Weight | 500 mg |
| Generic | Capecitabine |
| Manufacturer | Aristopharma Ltd. |
| Available in | English বাংলা |
Capecitin Tablet 500 mg is a prodrug that is converted into 5-fluorouracil (5-FU) in the liver and tumor tissues. 5-FU interferes with DNA synthesis by inhibiting thymidylate synthase, an enzyme crucial for the synthesis of thymidine, a DNA building block. This inhibition leads to the disruption of DNA replication and repair, ultimately inducing cancer cell death.
Patients may start to see clinical improvement within a few weeks of starting capecitabine therapy. However, the full therapeutic effect can take several cycles of treatment to become apparent, with tumor response often assessed after 8 to 12 weeks of therapy.
Capecitin Tablet 500 mg is well absorbed from the gastrointestinal tract. Peak plasma concentrations are typically reached within 1 to 2 hours after oral administration. The drug’s bioavailability is about 70%, and it is rapidly converted to 5-FU in the liver and tumor tissues.
Capecitin Tablet 500 mg and its metabolites are primarily eliminated through the kidneys. Approximately 90% of the drug is excreted in the urine, with less than 5% of the dose excreted in feces. The metabolism to 5-FU is also a significant pathway for elimination.
The standard dosage of capecitabine is:
Capecitin Tablet 500 mg is administered orally in the form of tablets. It should be taken with water within 30 minutes after a meal, typically twice daily. The exact dosing schedule may vary based on the specific cancer being treated and the patient’s overall health.
Common side effects of capecitabine include:
Toxicity can manifest as severe gastrointestinal distress, dehydration, and significant myelosuppression. The primary management of toxicity involves dose reduction or discontinuation of therapy, supportive care, and symptomatic treatment. Monitoring blood counts and liver function is essential during treatment.
Precautions include:
Capecitin Tablet 500 mg may interact with other medications, including:
Use capecitabine with caution in patients with:
Drug interactions include:
Capecitin Tablet 500 mg should be taken with food, within 30 minutes of a meal, to reduce gastrointestinal irritation. Food intake does not significantly affect the absorption of capecitabine, but taking it with food may help minimize side effects.
Capecitin Tablet 500 mg is classified as a Category D drug for pregnancy, indicating that there is evidence of risk to the fetus based on human studies. It should be used during pregnancy only if the potential benefit justifies the potential risk. Women of childbearing potential should use effective contraception during treatment.
Capecitin Tablet 500 mg is excreted in breast milk. It is generally advised to avoid breastfeeding during capecitabine treatment due to potential risk to the infant. Women should consult their healthcare provider regarding alternatives or the need to discontinue breastfeeding.
In the case of acute overdose, symptoms may include severe gastrointestinal toxicity, dehydration, and signs of significant myelosuppression. Treatment involves supportive care, including hydration, symptomatic management, and monitoring for adverse effects. There is no specific antidote for capecitabine overdose.
Capecitin Tablet 500 mg is contraindicated in patients with:
Take capecitabine as prescribed by your healthcare provider. Adhere to the dosing schedule and administration instructions, typically taking the medication twice daily with food. Complete the full course of therapy and consult your healthcare provider if you have any questions or experience severe side effects.
Store capecitabine at room temperature, away from moisture and heat. Keep it in its original container and out of reach of children. Check the expiration date and do not use the medication past its expiry date.
The volume of distribution of capecitabine is approximately 1.2 L/kg, indicating the extent to which the drug distributes into body tissues. This distribution helps in understanding the drug's effectiveness and its ability to reach target tissues.
The terminal half-life of capecitabine is approximately 1 hour. The short half-life contributes to the need for multiple daily doses to maintain effective therapeutic levels and ensure optimal drug exposure.
Capecitin Tablet 500 mg clearance is primarily renal, with around 90% of the drug excreted in the urine. The drug's clearance rate may be influenced by renal function and may require adjustment in patients with renal impairment to avoid toxicity.
See in details version Capecitin Tablet 500 mg also Capecitin Tablet 500 mg in bangla